| Dr Michael Patrick Bunch, MD | |
|
266 Joule St, Alcoa, TN 37701-2422 | |
| (865) 984-3864 | |
| (865) 380-4095 |
| Full Name | Dr Michael Patrick Bunch |
|---|---|
| Gender | Male |
| Speciality | Pain Management |
| Experience | 16 Years |
| Location | 266 Joule St, Alcoa, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619104080 | NPI | - | NPPES |
| Q027118 | Medicaid | TN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | MD055456 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Blount Memorial Hospital | Maryville, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Blount Memorial Physician Group Inc | 6406844174 | 242 |
News Archive
Apexigen, Inc., a biopharmaceutical company discovering and developing innovative antibody drugs for the treatment of cancer and other life-threatening diseases, announced today the initiation of a Phase 1 clinical trial of APX005M, the company's lead proprietary anticancer program.
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Tamsulosin Hydrochloride Capsules USP, 0.4 mg, the generic version of Boehringer Ingelheim's benign prostatic hyperplasia treatment, Flomax.
In laboratory mouse experiments, researchers at The University of Texas M. D. Anderson Cancer Center have developed a way to use RNA interference (RNAi) so that it permanently hampers breast cancer development. The technique permanently silences activated STAT3, a crucial gene found in some human breast tumors, thus reducing the cancer's ability to become invasive.
Scientists in Sweden today reported a nanoengineering innovation that offers hope for treatment of cancer, infections and other health problems - conductive wires of DNA enhanced with gold which could be used to electrically measure hundreds of biological processes simultaneously.
"It was a chilling sight for anyone who saw it," said Professor Stephan Achenbach, president of the European Society of Cardiology, the world's largest organization of heart doctors.
› Verified 1 days ago
| Entity Name | Blount Memorial Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699710194 PECOS PAC ID: 6406844174 Enrollment ID: O20040503000547 |
News Archive
Apexigen, Inc., a biopharmaceutical company discovering and developing innovative antibody drugs for the treatment of cancer and other life-threatening diseases, announced today the initiation of a Phase 1 clinical trial of APX005M, the company's lead proprietary anticancer program.
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Tamsulosin Hydrochloride Capsules USP, 0.4 mg, the generic version of Boehringer Ingelheim's benign prostatic hyperplasia treatment, Flomax.
In laboratory mouse experiments, researchers at The University of Texas M. D. Anderson Cancer Center have developed a way to use RNA interference (RNAi) so that it permanently hampers breast cancer development. The technique permanently silences activated STAT3, a crucial gene found in some human breast tumors, thus reducing the cancer's ability to become invasive.
Scientists in Sweden today reported a nanoengineering innovation that offers hope for treatment of cancer, infections and other health problems - conductive wires of DNA enhanced with gold which could be used to electrically measure hundreds of biological processes simultaneously.
"It was a chilling sight for anyone who saw it," said Professor Stephan Achenbach, president of the European Society of Cardiology, the world's largest organization of heart doctors.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael Patrick Bunch, MD 103 W Broadway Ave, Maryville, TN 37801-4703 Ph: (865) 273-1752 | Dr Michael Patrick Bunch, MD 266 Joule St, Alcoa, TN 37701-2422 Ph: (865) 984-3864 |
News Archive
Apexigen, Inc., a biopharmaceutical company discovering and developing innovative antibody drugs for the treatment of cancer and other life-threatening diseases, announced today the initiation of a Phase 1 clinical trial of APX005M, the company's lead proprietary anticancer program.
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Tamsulosin Hydrochloride Capsules USP, 0.4 mg, the generic version of Boehringer Ingelheim's benign prostatic hyperplasia treatment, Flomax.
In laboratory mouse experiments, researchers at The University of Texas M. D. Anderson Cancer Center have developed a way to use RNA interference (RNAi) so that it permanently hampers breast cancer development. The technique permanently silences activated STAT3, a crucial gene found in some human breast tumors, thus reducing the cancer's ability to become invasive.
Scientists in Sweden today reported a nanoengineering innovation that offers hope for treatment of cancer, infections and other health problems - conductive wires of DNA enhanced with gold which could be used to electrically measure hundreds of biological processes simultaneously.
"It was a chilling sight for anyone who saw it," said Professor Stephan Achenbach, president of the European Society of Cardiology, the world's largest organization of heart doctors.
› Verified 1 days ago
Dr. Bruce M Hairston, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 266 Joule St, Alcoa, TN 37701 Phone: 865-984-3864 Fax: 865-380-4095 |